This company has been marked as potentially delisted and may not be actively trading. NASDAQ:VBIV VBI Vaccines (VBIV) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About VBI Vaccines Stock (NASDAQ:VBIV) Get VBI Vaccines alerts:Sign Up Key Stats Today's Range$0.07▼$0.0750-Day Range$0.02▼$0.7952-Week Range$0.06▼$1.35VolumeN/AAverage Volume3.66 million shsMarket Capitalization$1.87 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview VBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited; and the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts. Read More Receive VBIV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for VBI Vaccines and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VBIV Stock News HeadlinesVBI Vaccines Restructures and Acquired by K2 VBI TrustJanuary 3, 2025 | tipranks.comVBI Vaccines Issues Voluntary Nationwide Recall of all PreHevbrio Vaccine Due to Discontinuation of Company OperationsNovember 15, 2024 | businesswire.comMajor Buy Alert Issued for August 31stKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 people worldwide. His system has flagged a handful of stocks worth watching ahead of August 31st. See which stocks his AI research platform is flagging right now. | TradeSmith (Ad)Why Is VBI Vaccines (VBIV) Stock Up 62% Today?August 6, 2024 | investorplace.comVBI Vaccines to be delisted from Nasdaq following restructuringAugust 4, 2024 | investing.comVBI Vaccines Provides an Update on its Restructuring ProceedingsAugust 3, 2024 | finance.yahoo.comVBI Vaccines secures court protection for restructuringAugust 1, 2024 | investing.comVBI Vaccines Initiates Restructuring Proceedings Under CCAA to Implement a Review of its Strategic AlternativesJuly 30, 2024 | stockhouse.comSee More Headlines VBIV Stock Analysis - Frequently Asked Questions How were VBI Vaccines' earnings last quarter? VBI Vaccines Inc. (NASDAQ:VBIV) issued its earnings results on Monday, March, 13th. The biopharmaceutical company reported ($1.60) EPS for the quarter, missing analysts' consensus estimates of ($1.40) by $0.20. The biopharmaceutical company earned $0.29 million during the quarter, compared to analysts' expectations of $1.98 million. VBI Vaccines had a negative net margin of 881.79% and a negative trailing twelve-month return on equity of 525.42%. When did VBI Vaccines' stock split? Shares of VBI Vaccines reverse split before market open on Wednesday, April 12th 2023.The 1-20 reverse split was announced on Wednesday, April 12th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, April 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of VBI Vaccines own? Based on aggregate information from My MarketBeat watchlists, some other companies that VBI Vaccines investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Pfizer (PFE) and Novavax (NVAX). Company Calendar Last Earnings3/13/2023Today8/21/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:VBIV CIK764195 Webwww.vbivaccines.com Phone(617) 830-3031FaxN/AEmployees22Year Founded2001Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$92.84 million Net Margins-881.79% Pretax Margin-881.79% Return on Equity-525.42% Return on Assets-45.87% Debt Debt-to-Equity RatioN/A Current Ratio0.34 Quick Ratio0.21 Sales & Book Value Annual Sales$9.41 million Price / Sales0.20 Cash FlowN/A Price / Cash FlowN/A Book Value$0.32 per share Price / Book0.20Miscellaneous Outstanding Shares28,682,000Free Float25,713,000Market Cap$1.87 million OptionableNo Data Beta2.18 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:VBIV) was last updated on 8/22/2026 by MarketBeat.com Staff. From Our PartnersThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredYour Free Report (Inside)A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | Sponsored23,281 stocks. Only ONE survived.One American energy producer just cleared a screen of 23281 stocks for elite operating profits, double-digit r...Monument Traders Alliance | SponsoredSomeone just dumped the biggest gold fund.Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...Behind the Markets | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VBI Vaccines Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share VBI Vaccines With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VBIV Stock Alerts